Interrelation between the development of atherosclerosis and the evolution of cancer
Keywords:
atherosclerosis, cancer, metabolic pathways, molecular mechanismsAbstract
Introduction: Cardiovascular diseases and cancer are two chronic pathologies and constitute the main causes of morbidity and mortality worldwide. Molecular mechanisms, metabolic pathways and common risk factors are shared in the development of atherosclerosis and the evolution of cancer.
Objective: To delve deeper into the interrelationship between atherosclerosis and cancer.
Methods: A documentary review was carried out that included articles from journals indexed in databases PubMed/Medline, SciElo, Scopus and the Google academic search engine, in the period from December 2024 to February 2025, related to the interrelationship between atherosclerosis and cancer, pathophysiological bases, molecular mechanisms and risk factors. 32 original articles were reviewed in the period 2015-2024, in Spanish and English languages, and 23 were referenced. The terms for the search included, atherosclerosis, cancer, risk factors, metabolic pathways, molecular mechanisms.
Development: Atherosclerosis shares biological mechanisms and metabolic pathways with the tumor phenotype and predisposes to metastasis. Several risk factors allow us to interpret the interrelationship between both diseases, such as obesity, smoking, dyslipidemia, and unhealthy diets. Both processes share the mechanisms of inflammation, proliferation and apoptosis in their evolution, and the genesis of vascular disease.
Conclusions: Atherosclerosis and cancer share common pathophysiological characteristics in blood vessels, risk factors and metabolic pathways that strengthen their interrelation and are the main causes of morbidity and mortality in the world.
Keywords: atherosclerosis; cancer; metabolic pathways; molecular mechanisms.
References
1. Organización Mundial de la Salud. Métodos y fuentes de datos de la OMS para las estimaciones de la carga mundial de morbilidad 2000-2019. [Internet]. Suiza, Ginebra; 2020 [acceso:25/01/2025]. Disponible en: https://www.paho.org/es/ noticias/9-12-2020-oms-revela-principales-causas-muerte-discapacidad-mundo-2000-2019
2. Consorcio Global de Riesgo Cardiovascular. Efecto global de los factores de riesgo modificables en la enfermedad cardiovascular y la mortalidad. N Engl J Med [Internet]. 2023 [acceso: 25/01/2025]; 389:1273–1285. Disponible en: https://www-nejm-org.translate.goog/doi/full/10.1056/NEJMoa2206916?xtrsl=en&_x_tr_tl=es&_x_tr_hl=es&_x_tr_pto=tc
3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Estadísticas mundiales sobre el cáncer 2020: estimaciones de GLOBOCAN sobre la incidencia y la mortalidad en todo el mundo para 36 tipos de cáncer en 185 países. CA Cancer J Clin [Internet]. 2021 [acceso: 23/01/2025]; 71: 209–249. Disponible en: https://acsjournals-onlinelibrary-wiley-com.translate.goog/doi/full/10.3322/caac.21660?_x_tr_sl=en&_x_tr_tl=es&_x_tr_hl=es&_x_tr_pto=tc
4. Colaboradores de GBD 2019 sobre factores de riesgo de cáncer. La carga mundial de cáncer atribuible a factores de riesgo, 2010-2019: un análisis sistemático para el Estudio de la carga mundial de enfermedad 2019. Lancet [Internet]. 2022 [acceso: 25/01/2025]; 400 (10353): 563–591.Disponible en: https://www-sciencedirect-com.translate.goog/science/article/pii/S0140673622014386?xtrsl=en&_x_tr_tl=es&_x_tr_hl=es&_x_tr_pto=tc
5. Koelwyn GJ, Aboumsallem JP, Moore KJ, de Boer RA. Oncología cardíaca inversa: exploración de los efectos de la enfermedad cardiovascular en la patogénesis del cáncer. J Mol Cell Cardiol [Internet]. 2022 [acceso: 25/01/2025]; 163: 1-8. Disponible en: https://www-mdpi-com.translate.goog /1422-0067/25/8/4232?xtrsl=en&xtrtl=es &x_tr_hl=es&_x_tr_pto=tc
6. Gallucci G, Turazza FM, Inno A, Canale ML, Silvestris N, Farì R, Navazio A, Pinto C, Tarantini L. Aterosclerosis y la relación bidireccional entre el cáncer y la enfermedad cardiovascular: del laboratorio a la cabecera del paciente, parte 1. Revista internacional de ciencias moleculares. 2024; 25(8): 4232. DOI: https://doi.org/10.3390/ijms25084232
7. Lau ES, Paniagua SM, Liu E, Jovani M,Li SX,Takvorian K et al. Los factores de riesgo cardiovascular se asocian con el cáncer futuro. JACC Cardio Oncol [Internet]. 2021 [acceso: 15/01/2025]; 3 (1): 48–58. Disponible en: https://www.jacc. org/doi/10.1016 /j.jaccao.2020.12.003
8. Hibler, EA; Lloyd-Jones, DM Abordar el “suelo común” de los factores de riesgo de enfermedades cardiovasculares y cáncer. JACC Cardio Oncol [Internet]. 2021 [acceso: 15/01/2025]; 3(1): 59–61. Disponible en: https://pmc-ncbi-nlm-nih-gov.translate.goog/articles/PMC11049833/?x_tr_sl=en&x_tr_tl=es&xtrhl=es & x_tr_pto=tc
9. Basatemur GL, Jorgensen HF, Clarke MCH, Bennett MR, Mallat Z. Vascular smooth muscle cells in atherosclerosis. Nat Rev Cardiol [Internet]. 2019 [acceso: 15/01/2025]; 12:727-744. Disponible en: https://pubmed.ncbi.nlm.nih .gov/31243391/
10. Pan H , Ho SE , Xue CH , Cui J , Johanson QS , Sachs N ,et al. Atherosclerosis Is a Smooth Muscle Cell–Driven Tumor-Like Disease. Circulación [Internet]. 2024 [acceso: 15/01/2025]; 149 (24): 1885-1898. Disponible en: https://www. ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.067587?url_ver=Z39.88-2003 &rfr_id=ori:rid:crossref.org &rfr_dat=cr_pub%20%200pubmed
11. Pan H, Xue C, Auerbach BJ, Fan J, Bashore AC, Cui J, et al. La genómica de células individuales revela un nuevo estado celular durante el cambio fenotípico de las células musculares lisas y posibles dianas terapéuticas para la aterosclerosis en ratones y humanos. Circulación [Internet]. 2020 [acceso: 15/01/2025]; 142: 2060-2075. Disponible en: https://www-ahajournals-org.translate.goog /doi/10.1161/CIRCULATIONAHA.120.048378?cookieSet=1&xtr_sl=en&xtr_ tl=es&_x_tr_hl=es&_x_tr_pto=tc
12. Fernández Rúa JM. La aterosclerosis y la progresión del cáncer comparten mecanismos moleculares. Biotech Cardiovasc Med [Internet]. 2022 [acceso: 15/01/2025]; 9: 849538. Disponible en: https://biotechmagazineandnews.com/la-aterosclerosis-y-la-progresion-del-cancer-comparten-mecanismos-moleculares/
13. Yuhong D, Zhixing L, Li Ch, Weiping Z, Dandan S. Relación entre el cáncer y los marcadores funcionales y estructurales de la aterosclerosis subclínica: una revisión sistemática y un metanálisis. Front Cardiovasc Med [Internet]. 2022 [acceso: 15/01/2025]; 9:849538. Disponible en: https://pmc.ncbi.nlm. nih.gov/articles /PMC9115552/
14. Oh CM, Lee D, Kong HJ, Lee S, Won YJ, Jung KW, et al. Causas de muerte entre pacientes con cáncer en la era de la supervivencia al cáncer en Corea: atención al suicidio y la mortalidad cardiovascular. Cancer Med [Internet]. 2020 [acceso: 15/01/2025]; 9(5):1741-52. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles /PMC7050076/
15. Margraf A , Perretti M .Plasticidad de las células inmunitarias en la inflamación: información sobre la descripción y regulación de los fenotipos de las células inmunitarias. Células [Internet]. 2022 [acceso: 15/01/2025];11(11):1824. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC9180515/pdf/cells-11-01824.pd
16. Río Solá ML, Losa Rodríguez R, Aguirre Gervás B, Gonzalo Benito H. Influencia del estrés oxidativo en la evolución de la aterosclerosis carotídea. Angiología [Internet]. 2023 [acceso:06/02/2025]; 75(6): 349-361. Disponible en: https:// scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0003-3170202300060 0002
17. Ortiz Escarza Jorge Manuel, Medina López Manuel Eusebio. Estrés oxidativo ¿un asesino silencioso? Educ quím [Internet]. 2020 [acceso:06/02/ 2025]; 31(1): 1-11. Disponible en: https://www.scielo.org.mx/scielo.php?script=sci_arttext &pid=S0187-893X2020000100002
18. Park HB; Arsanjani R, Hong SJ, Yi JJ, Yi SW. Impacto de la hipertrigliceridemia en la mortalidad cardiovascular según el colesterol de lipoproteínas de baja densidad en una población de 15,6 millones. Eur. J Prev Cardiol [Internet]. 2024 [acceso:06/02/2025];31(3):280–290. Disponible en: https://pubmed.ncbi. nlm.nih.gov/37850354/
19. Tao H, Zhong X, Zeng A and Song L Unveiling the veil of lactate in tumor- associated macrophages: a successful strategy for immunometabolic therapy. Immunol [Internet]. 2023 [acceso:08/02/2025]; 14:1208870. Diponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC10411982/pdf/fimmu-14-1208870 .pdf
20. Martí Líndez AA, Reith W. Arginine dependent immune responses. Cellular and Molecular Life Sciences [Internet]. 2021 [acceso:06/02/2025]; 78 (13): 5303–5324. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC8257534/
21. Lee-Rueckert M, Lappalainen J, Kovanen PT, Escola-Gil Lipid-Laden Macrophages and Inflammation in Atherosclerosis and Cancer: An Integrative View JC. Cardiovasc Med [Internet]. 2022 [acceso:04/02/2025]; 9:777822. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC8882850/
22. Walter G. Land. The Role of Damage-Associated Molecular Patterns in Human Diseases. Part I - Promoting inflammation and immunity SQU. Medical Journal [Internet]. 2015 [acceso:06/02/2025]; 15 (1): 9-21. Disponible en: https://pmc. ncbi.nlm.nih.gov/articles/PMC4318613/pdf /squmj1501-e9-21.pdf
23. Hernández Barrios DO. La Intersección entre la Aterosclerosis y la Progresión del Cáncer: Mecanismos Moleculares, Rutas Metabólicas y Respuesta Inmune. Linkedin [Internet]. 2024 [acceso:16/02/2025]. Disponible en: https://es.linkedin. com/pulse/la-intersecci%C3%B3n-entre-aterosclerosis-y-progresi%C3%B3n-del-fowcc
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Yinett Hernández León, Lina Isabel Rodríguez Hernández, Liuba Luisa Arteche Hidalgo
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The authors retain copyright and all unrestricted publication rights.
Medicoquirúrgicas Research is licensed under the Creative Commons Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0) and follows the SciELO Publishing Schema (SciELO PS) for publishing in XML format.
You are free to:
- Share — copy and redistribute the material in any medium or format.
- Adapt — remix, transform, and build upon the material.
The license cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do this in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
Non-Commercial — You may not use the material for commercial purposes.
No Additional Restrictions — You may not apply legal terms or technological measures that legally restrict others from making any use permitted by the license.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where their use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all the permissions you need for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
